tiprankstipranks
Advertisement
Advertisement

ZVRA Stock Latest News

Spruce Biosciences appoints Quartel as Chief Medical Officer
The FlySpruce Biosciences appoints Quartel as Chief Medical Officer
7d ago
SPRB
ZVRA
Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim
PremiumThe Fly
Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim
7d ago
ZVRA
Zevra Therapeutics price target lowered to $24 from $27 at BTIG
PremiumThe Fly
Zevra Therapeutics price target lowered to $24 from $27 at BTIG
7d ago
ZVRA
Zevra Therapeutics price target lowered to $20 from $29 at Canaccord
PremiumThe Fly
Zevra Therapeutics price target lowered to $20 from $29 at Canaccord
7d ago
ZVRA
Midday Fly By: Intel reports Q2 beat, Anduril in talks for $100B valuation
PremiumThe Fly
Midday Fly By: Intel reports Q2 beat, Anduril in talks for $100B valuation
9d ago
BP
EW
EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright
PremiumThe FlyEU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright
9d ago
ZVRA
Morning Movers: American Express dips after second quarter report
Premium
The Fly
Morning Movers: American Express dips after second quarter report
9d ago
VZ
AXP
Zevra Therapeutics down 30% at $8.78 after negative CHMP opinion on arimoclomol
Premium
The Fly
Zevra Therapeutics down 30% at $8.78 after negative CHMP opinion on arimoclomol
10d ago
ZVRA
Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA
PremiumThe Fly
Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA
10d ago
ZVRA
Zevra Therapeutics: New Infant MIPLYFFA Data Reinforce Core NPC Role; Buy Rating and $26 Price Target Reiterated
PremiumRatings
Zevra Therapeutics: New Infant MIPLYFFA Data Reinforce Core NPC Role; Buy Rating and $26 Price Target Reiterated
1M ago
ZVRA
Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports
PremiumThe Fly
Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports
1M ago
ZVRA
Zevra Therapeutics chief medical officer to step down
PremiumThe Fly
Zevra Therapeutics chief medical officer to step down
2M ago
ZVRA
Zevra Therapeutics price target raised to $35 from $25 at Maxim
PremiumThe FlyZevra Therapeutics price target raised to $35 from $25 at Maxim
2M ago
ZVRA
Zevra Therapeutics price target raised to $29 from $25 at Guggenheim
Premium
The Fly
Zevra Therapeutics price target raised to $29 from $25 at Guggenheim
2M ago
ZVRA
Zevra Therapeutics price target raised to $27 from $23 at BTIG
Premium
The Fly
Zevra Therapeutics price target raised to $27 from $23 at BTIG
2M ago
ZVRA
Zevra Therapeutics price target raised to $29 from $24 at Canaccord
PremiumThe Fly
Zevra Therapeutics price target raised to $29 from $24 at Canaccord
2M ago
ZVRA
Analyst Reiterates Buy on Zevra as Extended MIPLYFFA Patent Protection and Cash Generation Support Unchanged $26 Price Target
PremiumRatings
Analyst Reiterates Buy on Zevra as Extended MIPLYFFA Patent Protection and Cash Generation Support Unchanged $26 Price Target
2M ago
ZVRA
Zevra Therapeutics price target raised to $25 from $18 at Citizens
PremiumThe Fly
Zevra Therapeutics price target raised to $25 from $18 at Citizens
2M ago
ZVRA
Extended U.S. Patent Protection for Miplyffa Underpins Buy Rating and Long-Term Upside for Zevra
PremiumRatings
Extended U.S. Patent Protection for Miplyffa Underpins Buy Rating and Long-Term Upside for Zevra
2M ago
ZVRA
Zevra Therapeutics price target raised to $34 from $24 at Cantor Fitzgerald
PremiumThe FlyZevra Therapeutics price target raised to $34 from $24 at Cantor Fitzgerald
2M ago
ZVRA
Zevra Therapeutics announces Orange Book listing of Miplyffa patent
Premium
The Fly
Zevra Therapeutics announces Orange Book listing of Miplyffa patent
2M ago
ZVRA
Zevra Investors Reelect Directors, Reject Governance Structure Change
Premium
Company Announcements
Zevra Investors Reelect Directors, Reject Governance Structure Change
2M ago
8K
ZVRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >